The lead program, GE8820, has demonstrated deep and sustained IgG4 depletion in various models, giving it broad potential across numerous disease settings.
Organizations Involved
Novo Holdings, Catalio Capital Management, LifeArc Ventures, QIA, Sofinnova Partners, 5AM Ventures, Roche Ventures, Bristol Myers Squibb, Agent Capital, MP Healthcare Venture Management, Sixty Degree Capital
Company Description
GlycoEra AG is a biotechnology company dedicated to developing best-in-class protein degraders to transform the treatment of autoimmune diseases. Harnessing the power of glycoengineering to precisely target and degrade circulating, disease-causing proteins, GlycoEra is advancing a differentiated platform and pipeline of therapies targeting autoimmune diseases.
Market
Autoimmune Diseases
Location
Wädenswil,
Switzerland
Coinvestors
Novo Holdings, Catalio Capital Management, LifeArc Ventures, QIA, Sofinnova Partners, 5AM Ventures, Roche Ventures, Bristol Myers Squibb, Agent Capital, MP Healthcare Venture Management, Sixty Degree Capital